


## Data Sheet

<b>Product Name:</b>	Pafuramidine
<b>Cat. No.:</b>	CS-1470
<b>CAS No.:</b>	186953-56-0
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>20</sub> N <sub>4</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	364.40
<b>Target:</b>	Parasite
<b>Pathway:</b>	Anti-infection
<b>Solubility:</b>	H <sub>2</sub> O : < 0.1 mg/mL (insoluble); DMSO : 33.33 mg/mL (91.47 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

Pafuramidine (DB289) is an orally bioavailable prodrug of furamidine, which has clinical activity against *Pneumocystis pneumonia*. IC<sub>50</sub> Value: 4.5 nM (In vitro inhibitory activity against *Trypanosoma brucei rhodesiense*) [4] Target: Antiparasitic DB289 (pafuramidine maleate; 2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) is a prodrug of DB75 (furamidine dihydrochloride; 2,5-bis(4-guanylphenyl)furan dihydrochloride), an aromatic dication related to pentamidine that has demonstrated good efficacy against African trypanosomiasis, *Pneumocystis carinii pneumonia*, and malaria, but lacks adequate oral availability. in vitro: The results of this investigation suggest that DB75 inhibits mitochondrial function. Yeast cells relying upon mitochondrial metabolism for energy production are especially sensitive to DB75 [1]. in vivo: Clearance of DB289 approximated the liver plasma flow and its large volume of distribution was consistent with extensive tissue binding. Plasma protein binding of DB289 was 97 to 99% in four animal species and humans, but that of DB75 was noticeably less and more species- and concentration-dependent [2]. Despite excellent oral activity against early-stage sleeping sickness, oral administration of DB289 exhibited limited efficacy in mouse models of late-stage disease [3]. Clinical trial: DB289, a novel orally active prodrug of DB75, is undergoing phase IIb clinical trials for early-stage human African trypanosomiasis, *Pneumocystis jiroveci carinii pneumonia*, and malaria [1].

### References:

- [1]. Lanteri CA, Trumpower BL, Tidwell RR, DB75, a novel trypanocidal agent, disrupts mitochondrial function in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother*. 2004 Oct;48(10):3968-74.
- [2]. Midgley I, Fitzpatrick K, Taylor LM, Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride). *Drug Metab Dispos*. 2007 Jun;35(6):955-67.
- [3]. Sturk LM, Brock JL, Bagnell CR, Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. *Acta Trop*. 2004 Jul;91(2):131-43.
- [4]. In vitro inhibitory activity against *Trypanosoma brucei rhodesiense* - BioAssay Summary.

### CAIndexNames:

Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy-

### SMILES:

N=C(C1=CC=C(C2=CC=C(C3=CC=C(C(C(NOC)=N)C=C3)O2)C=C1)NOC

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA